This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

The REBUILD Trial: Closure of the Abdominal Wall

Sponsored by AbSolutions Med Inc.

About this trial

Last updated 2 years ago

Study ID

CTP-0002

Status

Not yet recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
22 to 80 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 2 years ago

What is this trial about?

The main objective of this clinical trial is to demonstrate the safety and efficacy of REBUILD when used to support abdominal wall closure after laparotomy. The main question it aims to answer are whether the device when used to support suture in abdominal wall closure safely maintains apposition of the abdominis rectus muscles within a pre-defined distance. Participants will undergo standard of care laparotomy and the investigational device will be used to support the suture used to close the abdominal wall. Participants will have an MRI at 1-month after surgery to measure the distance between the abdominus rectus muscles.

What are the participation requirements?

Yes

Inclusion Criteria

1. Patient is 22-80 years of age

2. Patient is undergoing a midline laparotomy procedure

3. Patient is able to provide written informed consent

4. Patient is able and willing to comply with all study requirements

No

Exclusion Criteria

1. Patient has BMI > 40

2. Patients with available imaging measuring abdominal wall thickness < 5.7 mm or > 16.5 mm

3. Patient is scheduled for a palliative procedure or has a life expectancy of less than 12-months

4. Patient has mesh at the site of deployment

5. Patient has an ostomy within the planned midline closure site (4 cm either side of midline)

6. Patient has a CDC wound classification of Class IV

7. Patient has devitalized tissue present at the intended surgical site

8. Patient has any co-morbid conditions determined by the investigator to place them at a high risk of complications (e.g., severe cardiovascular disease, congestive heart failure NYHA Class III or IV, end-stage renal failure, liver cirrhosis, connective tissue disorder, poorly managed diabetes)

9. Patient is on any medication that the investigator determines creates a high risk for complications (e.g., antithrombotic, steroid, IV chemotherapy, immunosuppressive agent)

10. Patient has history of radiation therapy targeting the abdominal wall

11. Patient is participating in a concurrent investigational medical device study

12. Patient is pregnant or planning on becoming pregnant during the study period

13. Patient has a history of psychological condition, drug, or alcohol misuse which may interfere with their ability to be compliant with post-operative visits

Locations

Location

Status